Evidence map›Paper›PMID 25268377›Full record

ArticleBritish journal of cancer2014

SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma.

J Dhanda, A Triantafyllou, T Liloglou, H Kalirai, B Lloyd, R Hanlon, R J Shaw, D R Sibson, J M Risk

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

J DhandaDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
A Triantafyllou1] Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK [2] Regional Oral and Maxillofacial Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
T LiloglouDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
H KaliraiDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
B LloydDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
R HanlonRegional Oral and Maxillofacial Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
R J Shaw1] Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK [2] Regional Oral and Maxillofacial Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
D R SibsonDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
J M RiskDepartment of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
University of Liverpool · GBAintree University Hospitals NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtracapsular spread (ECS) in cervical lymph nodes is the single-most prognostic clinical variable in oral squamous cell carcinoma (OSCC), but diagnosis is possible only after histopathological examination. A promising biomarker in the primary tumour, alpha smooth muscle actin (SMA) has been shown to be highly prognostic, however, validated biomarkers to predict ECS prior to primary treatment are not yet available.

methodsIn 102 OSCC cases, conventional imaging was compared with pTNM staging. SERPINE1, identified from expression microarray of primary tumours as a potential biomarker for ECS, was validated through mRNA expression, and by immunohistochemistry (IHC) on a tissue microarray from the same cohort. Similarly, expression of SMA was also compared with its association with ECS and survival. Expression was analysed separately in the tumour centre and advancing front; and prognostic capability determined using Kaplan-Meier survival analysis.

resultsImmunohistochemistry indicated that both SERPINE1 and SMA expression at the tumour-advancing front were significantly associated with ECS (P<0.001). ECS was associated with expression of either or both proteins in all cases. SMA+/SERPINE1+ expression in combination was highly significantly associated with poor survival (P<0.001). MRI showed poor sensitivity for detection of nodal metastasis (56%) and ECS (7%). Both separately, and in combination, SERPINE1 and SMA were superior to MRI for the detection of ECS (sensitivity: SERPINE1: 95%; SMA: 82%; combination: 81%).

conclusionA combination of SMA and SERPINE1 IHC offer potential as prognostic biomarkers in OSCC. Our findings suggest that biomarkers at the invasive front are likely to be necessary in prediction of ECS or in therapeutic stratification.

Indexed as

ActinsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansImmunohistochemistryMagnetic Resonance ImagingMaleMiddle AgedMouth NeoplasmsPlasminogen Activator Inhibitor 1PrognosisACTA2 protein, humanActinsBiomarkers, TumorPlasminogen Activator Inhibitor 1SERPINE1 protein, human

Identifiers

PMID25268377
PMCPMC4260028
OpenAlexW2076275120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.